02 NPHLA Intelligence desk
For pharmacies, 503A compounders, 503B outsourcing facilities and the professionals who rely on them: official actions from the FDA and other regulators, tracked as they happen — with the original records attached.
Featured on this desk
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
NPHLA tracked 1 new official record on this desk today: 1 recall record.
Automated from official records1 source1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records3 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records3 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records2 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records2 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records2 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
On October 14, 2026, Medline initiated a product recall, market exit and discontinuation of all Medline Brand beds, rails, mattresses, and accessories (e.g., pendants and motor boxes) due to a potential fire hazard and entrapment risk, which may result in patient injury or dea…
Eros Apothecary of Indio, California is recalling Candy Power For Man Organic Honey because the product was found to contain undeclared tadalafil.
FOR IMMEDIATE RELEASE – November 12, 2026 - Tampa, Florida. Game Changer Products LLC is voluntarily recalling all lots of 10 Day Forecast capsules to the consumer level. FDA analysis has found the product to be tainted with sildenafil and acetaminophen. Sildenafil is an activ…
Worcester, New York – Family Farmstead Dairy is recalling all cheddar cheese products because it has the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and…
The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, a…
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
Abiomed is removing certain Impella Controllers with various hardware, firmware, and/or software updates based on a retrospective review of servicing records.
